![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Albert-Ludwigs-Universität, Freiburg, Germany
Received July 17, 2005; accepted October 6, 2005.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
i/o protein-coupled CB1 cannabinoid receptor is the primary neuronal target of the phytocannabinoid 
9-tetrahydrocannabinol and of the endogenous cannabinoids (endocannabinoids) anandamide and 2-arachidonylglycerol (Howlett et al., 2002
; Abood, 2005). The CB1 receptor is widely distributed in the central and the peripheral nervous system (Herkenham et al., 1991b; Mailleux and Vanderhaeghen, 1992; Tsou et al., 1998). Activation of CB1 receptors leads to presynaptic inhibition of synaptic transmission in many regions of the central and peripheral nervous system (Freund et al., 2003; Szabo and Schlicker, 2005).
The present work focuses on the neuronal connection between the caudate putamen and the globus pallidus (also called external or lateral globus pallidus). Globus pallidus neurons receive strong GABAergic input from medium spiny neurons of the caudate-putamen (striatopallidal projection neurons; Gerfen, 2004). The concentration of CB1 receptor protein in the globus pallidus is very high (Herkenham et al., 1991b; Mailleux and Vanderhaeghen, 1992; Tsou et al., 1998). Two kinds of observations support the idea that the majority of CB1 receptors in the globus pallidus is localized on axon terminals of striatopallidal GABAergic neurons. First, many, if not all, medium spiny neurons synthesize CB1 receptor mRNA (Mailleux and Vanderhaeghen, 1992; Matsuda et al., 1993; Hohmann and Herkenham, 2000). More specifically, all striatopallidal neurons (which synthesize the neurochemical marker preproenkephalin mRNA) synthesize CB1 receptor mRNA (Hohmann and Herkenham, 2000). Second, the density of CB1 receptors in the globus pallidus decreases strongly if medium spiny neurons in the caudate-putamen are experimentally damaged (Herkenham et al., 1991a).
The hypothesis of the present work was that activation of CB1 receptors in terminals of striatopallidal axons modulates GABAergic synaptic transmission between these axons and globus pallidus neurons. For testing the hypothesis, we carried out a comprehensive electrophysiological analysis of striatopallidal neurotransmission in mouse brain slices. In addition to studying effects of synthetic exogenous cannabinoid receptor agonists, we also searched for synaptic modulation by endocannabinoids.
Globus pallidus neurons receive GABAergic input not only from the caudate-putamen but also from neighboring globus pallidus neurons. For studying the effect of cannabinoids on striatopallidal neurotransmission, we selectively activated the striatopallidal pathway by stimulation in the caudate-putamen and recorded the resulting GABAergic synaptic currents in globus pallidus neurons.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
).
|
For recording, slices were fixed at the glass bottom of a superfusion chamber with a nylon grid on a platinum frame and superfused with ACSF at room temperature at a flow rate of 1.5 ml min-1. The ACSF was of the following composition: 126 mM NaCl, 1.2 mM NaH2PO4, 3 mM KCl, 1 mM MgCl2, 2.5 mM CaCl2, 26 mM NaHCO3, and 10 mM glucose, pH 7.3 to 7.4.
Patch-Clamp Recording Techniques. Neurons in slices were visualized with infrared video microscopy (Fig. 1A): the slices were transilluminated with infrared light and viewed with a Zeiss Axios-kop FS-2 microscope (Zeiss, Göttingen, Germany) equipped with differential interference contrast optics and a video camera. Pipettes were pulled from borosilicate glass and had resistances of 2 to 5 M
when filled with intracellular solution. Patch-clamp recordings were obtained with an EPC-9 amplifier under the control of TIDA software (HEKA Elektronik, Lambrecht, Germany). Series resistance compensation of 50% was usually applied. Data were filtered at 1 to 2.9 kHz and stored with sampling rates at least twice the filtering frequency. Series resistance was measured before and after recordings, and experiments with major changes in series resistance (>20%) were discarded. For characterization of neurons (Fig. 1), an intracellular solution of the following composition was used: 145 mM potassium gluconate, 0.1 mM CaCl2, 2 mM MgCl2, 5 mM HEPES, 1.1 mM EGTA, 5 mM ATP-Mg, and 0.3 mM GTP-Tris, pH 7.4.
Recording of Inhibitory Postsynaptic Currents (IPSCs), Miniature IPSCs (mIPSCs), and Muscimol-Evoked Currents. IPSCs, mIPSCs, and muscimol-evoked currents in globus pallidus neurons were recorded in whole-cell configuration at a holding potential of -60 mV with pipettes containing 142 mM CsCl, 1 mM MgCl2, 10 mM HEPES, 10 mM EGTA, 4 mM ATP-Na2, and 2 mM N-ethyl-lidocaine chloride, pH 7.4. The superfusion ACSF contained DNQX (10-5 M) and AP5 (2.5 x 10-5 M) to suppress fast glutamatergic neurotransmission. IPSCs were elicited every 2 to 15 s with a bipolar platinum/iridium electrode positioned in the caudate-putamen. Single rectangular electrical pulses (10- to 100-µs pulse width; 1- to 3-mA pulse amplitude) were delivered by an isolated stimulator. Usually, 10 IPSCs were averaged. Muscimol-evoked currents were evoked every 60 s by pressure ejection of muscimol (10-3 M) from a pipette positioned about 100 µm above the surface of the slice. Pressure pulses (100-ms pulse width; 35- to 70-kPa amplitude) were delivered by a Picopump 820 (World Precision Instruments, Berlin, Germany). Five muscimol-evoked currents were averaged for further evaluation. mIPSCs were recorded in the presence of tetrodotoxin (3 x 10-7 M) in 60-s periods and identified and analyzed using the MiniAnalysis software (version 5.2.6; Synaptosoft, Decatur, GA). For studying depolarization-induced suppression of inhibition (DSI), the pipette solution contained 147 mM CsCl, 1 mM MgCl2, 10 mM HEPES, 1 mM EGTA, 4 mM ATP-Na2, 0.4 mM GTP-Na, and 2 mM N-ethyl-lidocaine chloride, pH 7.4.
Flash Photolysis of Caged GABA. Globus pallidus neurons were patched with pipettes containing the CsCl-based intracellular solution used to record IPSCs. The slices were superfused with ACSF containing 
-aminobutyric acid--carboxy-2-nitrobenzyl-ester (CNB-caged GABA) (8 x 10-5 M). An ultraviolet flash light source was connected to the microscope via a quartz light guide and a special condenser (TILL Photonics, Gräfelfing, Germany). Flashes (illuminated spot size, 50 x 50 µm) were applied every 60 s.
Fluorescence Measurement of Calcium Concentrations in Globus Pallidus Neurons. The patch pipette contained the same intracellular solution which was used to study DSI and, in addition, the low-affinity calcium indicator (Kd for calcium, 2 x 10-5 M) Oregon Green 488 BAPTA-5N (final concentration in the pipette, 2 x 10-4 M).
Fluorescence intensity in globus pallidus neurons was determined with an imaging system consisting of Polychrome IV monochromatic light source, a cooled IMAGO VGA CCD camera, and TILLvision imaging software (all components from TILL Photonics). With the regularly used 40x objective lens and at 2-fold binning, the camera had a pixel size of 0.5 µm. For measuring Oregon Green fluorescence, the excitation wave length of the monochromatic light source was adjusted to 495 nm, and a dichroic filter of 505DRLP and a bandpass emission filter of 535AF45 was used (Omega Optical, Brattleboro, VT).
Fluorescence images were obtained at a frequency of 10 Hz (see Fig. 5B1). After a 10-s reference period, the neurons were depolarized from -60 mV to +30 mV for 5 s. Fluorescence changes were evaluated in regions of interest (ROIs); ROIs were selected in the soma and in primary and secondary dendrites. Fluorescence values were corrected for background fluorescence. Calibration of the calcium indicator and calculation of the calcium concentrations were carried out as described by Helmchen (2000).
|
): 1) AP, +0.1 mm (anteroposterior, rostrally from bregma); L, 2 mm (laterally from midline); and V, -3.5 mm (ventrally from the bregma-lambda plane); 2) AP, +0.6 mm; L, 2 mm; and V, -3.5 mm; and 3) AP, +1.1 mm; L, 1.5 mm; and V, -3.5 mm. Each injection lasted for 10 min, and the pipette was left in position for an additional 5 min. After the injections, the skin on the head was sutured, and metamizol (also called dipyron; 50 µg g-1) was administered intra-peritoneally for postoperative analgesia. After a survival period of 3 to 5 days, mice were killed, and oblique-sagittal slices, including the caudate-putamen and globus pallidus, were prepared (see "Brain Slices"). Fluorescence changes in the globus pallidus were evaluated with the imaging system described above. The excitation wavelength and the fluorescence filter set were also identical. Eight-fold binning was used; this resulted in a camera pixel size of 2 µm.
At each measurement period, 40 fluorescence images of the globus pallidus were recorded at 25 Hz (interimage interval, 40 ms) (see Fig. 9). The striatopallidal axons were stimulated in the caudate-putamen after the fifth image. Electrical stimulation caused an inhomogeneous increase in fluorescence in the globus pallidus, most likely because some axons were not properly loaded with the fluorescent dye. We decided to evaluate fluorescence in ROIs, in which the electrical stimulation caused the strongest fluorescence increases. Fluorescence values were corrected for background fluorescence. For further evaluation, ratios between stimulation-evoked fluorescence changes (F) and baseline fluorescence measured immediately before stimulation (F0) were calculated (F/F0 ratios).
|
Means ± S.E.M. are given throughout. Nonparametric statistical tests were used to identify significant differences. The two-tailed Mann-Whitney test was used for comparisons between groups (drug versus solvent); significant differences are indicated by an asterisk (*). The two-tailed Wilcoxon signed rank test was used for comparisons within groups (drug versus PRE); significant differences are indicated by + and #. p < 0.05 was taken as the limit of statistical significance, and only this level is indicated, even if p was < 0.01 or < 0.001.
Drugs. Drugs were obtained from the following sources. N-Ethyllidocaine chloride (QX-314) was from Alamone Labs (Jerusalem, Israel); Oregon Green 488 BAPTA-5N hexapotassium salt, Oregon Green 488 BAPTA-1 dextran (mol. wt. 10,000), and CNB-caged GABA were from Invitrogen (Leiden, The Netherlands); rimonabant (previously called SR141716A) was from Sanofi-Aventis (Chilly-Mazarin, France); NO-711 was from Sigma Chemie (Deisenhofen, Germany); and HU210, CP55940, 6,7-dinitroquinoxaline-2,3-dione (DNQX), DL-2-amino-5-phosphonopentanoic acid (AP5), quinpirole HCl, WIN55212-2, and tetrodotoxin were from Tocris Cookson (Bristol, UK).
The cannabinoid ligands WIN55212-2, CP55940, HU210, and rimonabant were dissolved in dimethylsulfoxide (DMSO). Stock solutions were stored at -20°C. Further dilutions were made with superfusion buffer; the final concentration of DMSO in the superfusion fluid was 1 ml l-1. Control solutions always contained the appropriate concentration of DMSO.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
(n = 19) and 29 ± 3 pF (n = 19), respectively. The properties of our neurons resemble the properties determined previously by Cooper and Stanford (2000). GABAergic striatopallidal neurotransmission was studied in all globus pallidus neurons, irrespectively of their electrophysiological properties.
Inhibitory Neurotransmission between the Caudate-Putamen and Globus Pallidus. Electrical stimulation with single pulses in the caudate-putamen in the presence of ionotropic glutamate receptor antagonists elicited typical GABAA receptor-mediated IPSCs in globus pallidus neurons (Fig. 2). The amplitude of IPSCs was 274 ± 23 pA (n = 92). The latency was 9.4 ± 1.2 ms (n = 92); this long latency is due to the long distance between the stimulation electrode in the caudate-putamen and the site of recording of IPSCs in the globus pallidus. The GABAA receptor antagonist bicuculline (2 x 10-5 M) abolished the IPSCs (Fig. 2A). The reversal potential was very near to the calculated chloride equilibrium potential (Fig. 2B). Finally, we tested whether a known modulator of striatopallidal neurotransmission caused the expected change in our preparation. The dopamine D2/D3-receptor agonist quinpirole (10-5 M) markedly inhibited striatopallidal neurotransmission (Fig. 2C) like dopamine did similarly in a previous study by activating D2 receptors (Cooper and Stanford, 2001).
|
|
|
In the next step, we wanted to determine the cannabinoid receptor subtype involved in the inhibition of neurotransmission by studying the interaction between WIN55212-2 and the CB1 cannabinoid receptor antagonist rimonabant. When superfused alone for 15 min, rimonabant (10-6 M) did not change the amplitude of IPSCs (Fig. 4). In the presence of rimonabant, WIN55212-2 (10-5 M) failed to depress IPSCs (Fig. 4).
Endocannabinoid-Mediated DSI at Striatopallidal Synapses. At many synapses, depolarization of the postsynaptic neuron leads to inhibition of transmitter release from the presynaptic axon terminal. This form of retrograde signaling is termed "depolarization-induced suppression of inhibition" (DSI) in the case of GABAergic synapses and "depolarization-induced suppression of excitation" (DSE) in the case of glutamatergic synapses. DSI and depolarization-induced suppression of excitation are frequently mediated by endocannabinoids, which are synthesized and released by depolarized postsynaptic neurons (for reviews, see Wilson and Nicoll, 2002; Freund et al., 2003; Diana and Marty, 2004). We searched for DSI at striatopallidal synapses.
An intracellular solution with low-calcium buffering capacity (EGTA, 1 mM) was used in these experiments. The striatopallidal axons were stimulated in the caudate-putamen every 2 s (Fig. 5A). DSI was elicited by raising the membrane potential of globus pallidus neurons from -60 mV to +30 mV for 5 s. DSI was elicited at first in the presence of solvent, then in the presence of the antagonist rimonabant. In the presence of solvent, the depolarization led to a small suppression of IPSCs: the maximal suppression was 27%, and the suppression was shorter than 8 s. Rimonabant was superfused at two concentrations, 10-6 and 10-5 M. Since the results obtained at the two concentrations were identical, the experiments were pooled. In the presence of rimonabant, the depolarization of the postsynaptic neuron no longer suppressed the IPSCs. Rather, a small potentiation occurred (Fig. 5A). Prevention of DSI by the cannabinoid antagonist suggests that endocannabinoids acting at CB1 receptors were involved.
Although it is generally accepted that endocannabinoid synthesis in postsynaptic neurons is triggered by an increase in intracellular calcium concentration, the depolarization-evoked increase in intracellular calcium concentration has been determined in only few studies (Glitsch et al., 2000; Wang and Zucker, 2001; Brenowitz and Regehr, 2003). Therefore, we decided to determine the calcium concentration increases in globus pallidus neurons. Globus pallidus neurons were loaded via the patch pipette with the low-affinity calcium indicator Oregon Green 488 BAPTA-5N (Fig. 5B). Neurons were depolarized like in experiments in which DSI was studied, i.e., from -60 mV to +30 mV for 5 s. In response to this depolarization, the calcium concentration in somatic and dendritic regions of globus pallidus neurons increased maximally to 14.5 and 9.9 µM, respectively.
|
First, we tested whether WIN55212-2 interferes with the activation of postsynaptic GABAA receptors on globus pallidus neurons by muscimol. Muscimol (10-3 M) was pressure-ejected from a pipette in the vicinity of the recorded neurons. During the initial reference period (PRE), muscimol-evoked currents had an amplitude of 268 ± 73 pA (n = 16). Figure 6 shows that the muscimol-evoked currents remained stable in solvent-treated slices. Superfusion with WIN55212-2 (10-5 M) did not elicit any effect (Fig. 6). Thus, WIN55212-2 did not interfere with the activation of postsynaptic GABAA receptors on globus pallidus neurons.
In the second set of experiments, postsynaptic GABAA receptors were activated by GABA released by photolysis of caged GABA. Slices were superfused with ACSF containing CNB-caged GABA (8 x 10-5 M). The recorded neuron was illuminated with flash light every 60 s. The flash elicited GABAA receptor-mediated currents: the currents were abolished by bicuculline (2 x 10-5 M) and reversed polarity near the calculated equilibrium potential of chloride (not shown). During the initial reference period (PRE), flash-evoked currents had an amplitude of 825 ± 123 pA (n = 12). The decay time constant (
) of flash-evoked currents was 64 ± 10 ms during the PRE period (n = 12). Flash-evoked currents remained stable in solvent-treated slices (Fig. 7, A and B). Superfusion of WIN55212-2 (10-5 M) affected neither the amplitude nor the time constant of flash-evoked currents (Fig. 7, A-C). Thus, WIN55212-2 did not interfere also with the activation of postsynaptic GABAA receptors when these receptors were activated with fast kinetics resembling physiological conditions. At the end of the experiments, the GABA uptake inhibitor NO-711 (2 x 10-5 M) was superfused. It did not change the amplitude of flash-evoked currents but significantly prolonged these currents (Fig. 7, A-C). This latter observation verifies that our method is suitable to detect changes in GABA uptake.
|
In the third series of experiments, a traditional analysis of mIPSCs was carried out. mIPSCs were isolated by tetrodotoxin (3 x 10-7 M). During the initial reference period (PRE), the frequency and amplitude of mIPSCs were 2.7 ± 0.7 Hz and 68 ± 8 pA (n = 10), respectively. In control experiments with solvent, the frequency and amplitude of mIPSCs remained constant (Fig. 8E). WIN55212-2 (10-5 M) changed neither the frequency (Fig. 8, A, D, and E) nor the amplitude of mIPSCs (Fig. 8, B, C, and E). Lack of effect of WIN55212-2 on the amplitude of mIPSCs indicates that the cannabinoid did not interfere with the effect of synaptically released GABA on postsynaptic globus pallidus neurons. This latter observation and the observations with muscimol and caged GABA all support—by exclusion of a postsynaptic action—a presynaptic mode of action of cannabinoids at inhibiting synaptic transmission. The lack of effect on mIPSC frequency suggests that the vesicular release machinery was not directly inhibited.
|
Slices were prepared from brains of mice in which the striatopallidal axons had been labeled with the calcium-sensitive fluorescent dye Oregon Green 488 BAPTA-1 dextran. Striatopallidal axons were stimulated in the caudate-putamen with a short series of pulses (four pulses at 100 Hz), and the stimulation-evoked fluorescence increase was observed in the globus pallidus with an imaging camera (Fig. 9).
The stimulation elicited a weak increase in fluorescence in the globus pallidus (compare Fig. 9, B and C). The site of fluorescence increase was determined by subtraction of the image obtained before stimulation (Fig. 9B) from the image obtained after stimulation (Fig. 9C). The subtraction image shown in Fig. 9D indicates an inhomogeneous increase in fluorescence. Three ROIs were selected, and further evaluations were based on these ROIs. Figure 9E shows the time pattern of stimulation-evoked fluorescence change at the three ROIs indicated in Fig. 9D. During the initial reference period (PRE), the peak F/F0 value was 0.065 ± 0.006 (n = 48).
The effects of the cannabinoid agonist WIN55212-2 were compared with the effects of solvent (Fig. 10, A-C). In addition, the consequences of sodium channel blockade by tetrodotoxin and calcium channel blockade by cadmium were also studied (Fig. 10, A-C). During superfusion of solvent, the calcium transient did not change (Fig. 10, A and B). When tetrodotoxin was superfused at the end of the solvent experiments, it abolished the calcium transients (Fig. 10, A and B; see also Fig. 9E). In the other group, WIN55212-2 (10-5 M) was superfused: it decreased the amplitude of the calcium transients by 22% (Fig. 10, A and C). When cadmium (10-4 M) was superfused at the end of the experiments, it greatly decreased the amplitude of the transients (Fig. 10, A and C).
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Striatopallidal neurotransmission was selectively activated by stimulation in the caudate-putamen. This approach allowed unambiguous localization of the cannabinoid effect to terminals of striatopallidal axons. The advantage of stimulation in the caudate-putamen versus stimulation in the globus pallidus for studying drug effects on the striatopallidal pathway has been recently shown by Cooper and Stanford (2001). Inhibition of neurotransmission by dopamine was seen only if stimulation occurred in the caudate-putamen. When the GABAergic input was stimulated in the vicinity of the recorded neurons in the globus pallidus, dopamine had only a minimal effect. Obviously, dopamine effects on the striatopallidal pathway were masked when intrapallidal GABAergic connections were additionally stimulated (Cooper and Stanford, 2001).
It is very likely that the receptors responsible for the inhibition of striatopallidal GABAergic neurotransmission are CB1 receptors. The inhibition was elicited by the synthetic drugs WIN55212-2 and CP55940. The two drugs belong to greatly differing chemical classes, but both of them are agonists at CB1 and CB2 receptors (Howlett et al., 2002; Pertwee, 2005). High concentrations of WIN55212-2 and CP55940 were necessary for the inhibition of neurotransmission. The reason is very likely the poor penetration of these substances into the brain slice, as impressively demonstrated by Brown et al. (2004). HU210 (10-6 M) was ineffective in our study, although it produced effects in other brain slice studies at this concentration (e.g., Gerdeman and Lovinger, 2001). It may be that the neurons recorded by us were located more deeply under the surface of the brain slice than in the other studies; this can hinder penetration of HU210 to the target neurons (see Brown et al., 2004). The CB1-selective antagonist rimonabant (Howlett et al., 2002; Pertwee, 2005) abolished the inhibition of IPSCs by WIN55212-2: this observation verifies the involvement of CB1 receptors. It has been recently observed that WIN55212-2 can elicit effects in the brain independently of CB1 receptors, and a novel type of cannabinoid receptor was postulated (Breivogel et al., 2001; Hájos and Freund, 2002). Since CP55940 does not elicit such a non-CB1 receptor-mediated effect (Breivogel et al., 2001), it is unlikely that non-CB1 receptors played a role in the present study.
In three kinds of experiments (1-3), WIN55212-2 did not interfere with the activation of postsynaptic GABAA receptors. 1) WIN55212-2 did not change the amplitude of currents evoked by muscimol in globus pallidus neurons. 2) Currents elicited by flash photolysis of caged GABA were also not changed. 3) Finally, the amplitude of mIPSCs was not altered. Since postsynaptic effects by WIN55212-2 can be excluded, it is very likely that WIN55212-2 (and CP55940) inhibited striatopallidal neurotransmission with a presynaptic mechanism. A further argument for a presynaptic action is the anatomical localization of the CB1 receptor. The presynaptic striatopallidal medium spiny neurons synthesize CB1 receptors, whereas the postsynaptic globus pallidus neurons generally do not (Mailleux and Vanderhaeghen, 1992; Matsuda et al., 1993; Hohmann and Herkenham, 2000).
The experiments with flash photolysis of caged GABA indicate that WIN55212-2, at the concentration causing strong presynaptic inhibition (10-5 M), does not influence GABA uptake. In a previous study (Maneuf et al., 1996a), WIN55212-2 depressed GABA uptake in the globus pallidus; however, higher concentrations were necessary for this effect (5-20 x 10-5 M). Systemically administered cannabinoids counteract the inhibition of globus pallidus neurons elicited by electrical stimulation in the caudate-putamen (Miller and Walker, 1996); the inhibition of the striatopallidal synapse as shown in the present brain slice study is the probable basis of this in vivo cannabinoid effect.
It is thought that activation of CB1 receptors leads to presynaptic inhibition by one of the following mechanisms (for review, see Szabo and Schlicker, 2005): opening of certain potassium channels, inhibition of voltage-dependent calcium channels, and direct interference with the vesicle release machinery. Lack of effect of WIN55212-2 on the frequency of action potential-independent mIPSCs indicates that the vesicle release machinery was not directly inhibited in the present study.
We used a novel technique for selective labeling of the striatopallidal axon terminals with a calcium-sensitive dye. The following measurements of calcium concentrations showed that cannabinoids depress the action potential-evoked increase in calcium concentration in striatopallidal axon terminals. This depression was very likely the reason for the decrease in GABA release. Although it is generally believed that cannabinoids can depress the action potential-evoked calcium influx into axon terminals, a cannabinoid-induced decrease in axon terminal calcium currents or concentrations has been demonstrated only in two brain regions, the cerebellar cortex (Diana et al., 2002; Brown et al., 2004; Daniel et al., 2004) and the brain stem (Kushmerick et al., 2004). Our experiments show that cannabinoids lower the calcium concentration in an additional region, the globus pallidus.
We did not attempt to clarify whether the depressed calcium response and the resulting inhibition of transmitter release are due to a primary action of cannabinoids on voltage-dependent calcium channels or potassium channels (potassium channel modulation can lead to changes in calcium channel activation). Some data suggest that cannabinoids cause presynaptic inhibition by primarily inhibiting calcium channels (Hoffman and Lupica, 2000; Liang et al., 2003; Brown et al., 2004). Other data point to potassium channels as the primary targets of cannabinoids causing presynaptic inhibition (Diana and Marty, 2003; Daniel et al., 2004).
The CB1 receptor antagonist rimonabant, superfused alone, did not enhance the amplitude of IPSCs, indicating that under the conditions of the present study endocannabinoids did not tonically inhibit GABA release in the globus pallidus. Depolarization of postsynaptic globus pallidus neurons induced a suppression of the striatopallidal IPSCs; i.e., DSI occurred. Abolishment of this suppression by rimonabant indicates that endocannabinoids released from postsynaptic neurons and acting at presynaptic CB1 cannabinoid receptors were involved in this phenomenon. The depolarization induced a robust increase in the intracellular calcium concentration in globus pallidus neurons—similar to increases observed previously in the hippocampus and the cerebellum (Wang and Zucker, 2001; Brenowitz and Regehr, 2003). Therefore, it is likely that the endocannabinoid synthesis in globus pallidus neurons was triggered by the increase in intracellular calcium concentration.
Compared with other brain regions, the extent and duration of DSI at the striatopallidal synapse was rather moderate, although the experimental conditions (age of animals, temperature during recording, composition of the intracellular solution, and duration and amplitude of the depolarizing pulse) were similar to those used in other brain regions (e.g., Wallmichrath and Szabo, 2002; Brenowitz and Regehr, 2003; Diana and Marty, 2003; Szabo et al., 2004; for reviews, see Wilson and Nicoll, 2002; Freund et al., 2003; Diana and Marty, 2004). The calcium measurements showed that the calcium concentration increased sufficiently in globus pallidus neurons. The reason for the weak DSI may be that the endocannabinoid synthesizing capacity of globus pallidus neurons is weak or that endocannabinoids do not properly diffuse to the CB1 receptor-bearing presynaptic axon terminals. It is noteworthy that in some regions DSI even does not occur, although presynaptic CB1 receptors are present (certain hippocampal synapses, Hoffman et al., 2003; synapses between caudate-putamen neurons, I. Freiman and B. Szabo, unpublished observations).
Cannabinoids microinjected into the globus pallidus or systemically administered cause catalepsy (Pertwee and Wickens, 1991; for review, see Sanudo-Pena et al., 1999). It has been suggested that inhibition of GABA uptake and the following enhancement of GABAergic neurotransmission in the globus pallidus is the reason for the catalepsy (Maneuf et al., 1996a,b). The present results unequivocally show that the principal effect of cannabinoids on GABAergic neurotransmission in the globus pallidus is inhibition of neurotransmission—GABA uptake was not significantly changed. Remarkably, cannabinoids also inhibit the glutamatergic subthalamopallidal neurotransmission (Freiman and Szabo, 2005). Altogether, there is no unambiguous explanation for the catalepsy induced by intrapallidal cannabinoid application. The explanation for the catalepsy elicited by systemically administered cannabinoids is even more difficult, because cannabinoids modulate GABAergic and glutamatergic neurotransmission in the basal ganglia at least at 11 sites (see Fig. 6 in Szabo and Schlicker, 2005).
In conclusion, the concentration of CB1 cannabinoid receptors in the globus pallidus is very high. The present study unequivocally clarified the function of these receptors. Activation of CB1 receptors on terminals of striatopallidal axons by exogenous cannabinoid agonists leads to presynaptic inhibition of GABAergic neurotransmission between these axons and globus pallidus neurons. Inhibition of the action potential-evoked increase in axon terminal calcium concentration is the event behind the presynaptic inhibition of GABA release. The presynaptic CB1 cannabinoid receptors can also be activated by endocannabinoids released by depolarized postsynaptic globus pallidus neurons.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
ABBREVIATIONS: ACSF, artificial cerebrospinal fluid; IPSC, inhibitory postsynaptic current; mIPSC, miniature inhibitory postsynaptic current; DNQX, 6,7-dinitroquinoxaline-2,3-dione; AP5, DL-2-amino-5-phosphonopentanoic acid; DSI, depolarization-induced suppression of inhibition; CNB-caged GABA, -aminobutyric acid--carboxy-2-nitrobenzyl-ester; ROI, region of interest; PRE, initial reference value determined before drug application; NO-711, 1-[2-[[(diphenylmethylene)imino]oxy]ethyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid HCl; HU210, (6aR)-trans-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol; CP55940, (-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)-phenyl]-trans-4-(3-hydroxy-propyl)-cyclohexanol; WIN55212-2, R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl] pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)-methanone mesylate; DMSO, dimethylsulfoxide; SOL, solvent.
Address correspondence to: Dr. Bela Szabo, Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Albert-Ludwigs-Universität, Albertstrasse 25, D-79104 Freiburg i. Br., Germany. E-mail: szabo{at}pharmakol.uni-freiburg.de
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Abood ME (2005) Molecular biology of cannabinoid receptors, in Handbook of Experimental Pharmacology: Cannabinoids (Pertwee R ed) vol 168, pp 81-115, Springer-Verlag, Heidelberg.
Breivogel CS, Griffin G, Di Marzo V, and Martin BR (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60: 155-163.
Brenowitz SD and Regehr WG (2003) Calcium dependence of retrograde inhibition by endocannabinoids at synapses onto Purkinje cells. J Neurosci 23: 6373-6384.
Brown SP, Safo PK, and Regehr WG (2004) Endocannabinoids inhibit transmission at granule cell to Purkinje cell synapses by modulating three types of presynaptic calcium channels. J Neurosci 24: 5623-5631.
Cooper AJ and Stanford IM (2000) Electrophysiological and morphological characteristics of three subtypes of rat globus pallidus neurone in vitro. J Physiol (Lond) 527: 291-304.
Cooper AJ and Stanford IM (2001) Dopamine D2 receptor mediated presynaptic inhibition of striatopallidal GABAA IPSCs in vitro. Neuropharmacology 41: 62-71.[CrossRef][Medline]
Daniel H, Rancillac A, and Crepel F (2004) Mechanisms underlying cannabinoid inhibition of presynaptic Ca2+ influx at parallel fibre synapses of the rat cerebellum. J Physiol (Lond) 557: 159-174.
Diana MA, Levenes C, Mackie K, and Marty A (2002) Short-term retrograde inhibition of GABAergic synaptic currents in rat Purkinje cells is mediated by endogenous cannabinoids. J Neurosci 22: 200-208.
Diana MA and Marty A (2003) Characterization of depolarization-induced suppression of inhibition using paired interneuron—Purkinje cell recordings. J Neurosci 23: 5906-5918.
Diana MA and Marty A (2004) Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Pharmacol 142: 9-19.[CrossRef][Medline]
Freiman I and Szabo B (2005) Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus. Neuroscience 133: 305-313.[CrossRef][Medline]
Freund TF, Katona I, and Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83: 1017-1066.
Gerdeman G and Lovinger DM (2001) CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 85: 468-471.
Gerfen CR (2004) Basal ganglia, in The Rat Nervous System (Paxinos G ed) pp 455-508, Elsevier Academic Press, San Diego.
Glitsch M, Parra P, and Llano I (2000) The retrograde inhibition of IPSCs in rat cerebellar Purkinje cells is highly sensitive to intracellular Ca2+. Eur J Neurosci 12: 987-993.[CrossRef][Medline]
Hájos N and Freund TF (2002) Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 43: 503-510.[CrossRef][Medline]
Helmchen F (2000) Calibration of fluorescent calcium indicators, in Imaging Neurons: A Laboratory Manual (Yuste R, Lanni F, and Konnerth A eds) pp 32.1-32.9, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
Herkenham M, Lynn AB, De Costa BR, and Richfield EK (1991a) Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 547: 267-274.[CrossRef][Medline]
Herkenham M, Lynn AB, Johnson MR, Melvin LS, De Costa BR, and Rice KC (1991b) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563-583.[Abstract]
Hoffman AF and Lupica CR (2000) Mechanisms of cannabinoid inhibition of GABAA synaptic transmission in the hippocampus. J Neurosci 20: 2470-2479.
Hoffman AF, Riegel AC, and Lupica CR (2003) Functional localization of cannabinoid receptors and endogenous cannabinoid production in distinct neuron populations of the hippocampus. Eur J Neurosci 18: 524-534.[CrossRef][Medline]
Hohmann AG and Herkenham M (2000) Localization of cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse 37: 71-80.[CrossRef][Medline]
Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202.
Kushmerick C, Price GD, Taschenberger H, Nagore P, Renden R, Wadiche JI, Duvoisin RM, Grandes P, and von Gersdorff H (2004) Retroinhibition of presynaptic Ca2+ currents by endocannabinoids released via postsynaptic mGluR activation at a calyx synapse. J Neurosci 24: 5955-5965.
Liang Y-C, Huang C-C, Hsu K-S, and Takahashi T (2003) Cannabinoid-induced presynaptic inhibition at the primary afferent trigeminal synapse of juvenile rat brainstem slices. J Physiol (Lond) 555: 85-96.[CrossRef][Medline]
Mailleux P and Vanderhaeghen J-J (1992) Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48: 655-668.[CrossRef][Medline]
Maneuf YP, Crossman AR, and Brotchie JM (1996a) Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse 22: 382-385.[CrossRef][Medline]
Maneuf YP, Nash JE, Crossman AR, and Botchie JM (1996b) Activation of the cannabinoid receptor by 9-tetrahydrocannabinol reduces -aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol 308: 161-164.[CrossRef][Medline]
Matsuda LA, Bonner TI, and Lolait SJ (1993) Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327: 535-550.[CrossRef][Medline]
Miller AS and Walker MJ (1996) Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. Eur J Pharmacol 304: 29-35.[CrossRef][Medline]
Paxinos G and Franklin KBJ (2001) The Mouse Brain in Stereotaxic Coordinates. Academic Press, San Diego.
Pertwee R (2005) Pharmacological actions of cannabinoids, in Handbook of Experimental Pharmacology: Cannabinoids (Pertwee R ed) vol 168, pp 1-51, Springer-Verlag, Heidelberg.
Pertwee RG and Wickens AP (1991) Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology 30: 237-244.[CrossRef][Medline]
Sanudo-Pena CM, Tsou K, and Walker MJ (1999) Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 65: 703-713.[CrossRef][Medline]
Szabo B and Schlicker E (2005) Effects of cannabinoids on neurotransmission, in Handbook of Experimental Pharmacology: Cannabinoids (Pertwee R ed) vol 168, pp 327-365,
Springer-Verlag, Heidelberg. Szabo B, Than M, Thorn D, and Wallmichrath I (2004) Analysis of the effects of cannabinoids on synaptic transmission between basket and Purkinje cells in the cerebellar cortex of the rat. J Pharmacol Exp Ther 310: 915-925.
Tsou K, Brown S, Sanudo-Pena MC, Mackie K, and Walker JM (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83: 393-411.[CrossRef][Medline]
Wallmichrath I and Szabo B (2002) Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse. Neuroscience 113: 671-682.[CrossRef][Medline]
Wang J and Zucker RS (2001) Photolysis-induced suppression of inhibition in rat hippocampal CA1 pyramidal neurons. J Physiol (Lond) 533.3: 757-763.
Wilson RI and Nicoll RA (2002) Endocannabinoid signaling in the brain. Science (Wash DC) 296: 678-682.
This article has been cited by other articles:
|
|
 |
|
  E. Benarroch Endocannabinoids in basal ganglia circuits: Implications for Parkinson disease Neurology, July 17, 2007; 69(3): 306 - 309. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sanchez-Pastor, X. Trujillo, M. Huerta, and F. Andrade Effects of Cannabinoids on Synaptic Transmission in the Frog Neuromuscular Junction J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 439 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hernandez, O. Ibanez-Sandoval, A. Sierra, R. Valdiosera, D. Tapia, V. Anaya, E. Galarraga, J. Bargas, and J. Aceves Co |
